

1 **Modelling of outbreaks of SARS-CoV-2 Omicron variants after easing**

2 **Dynamic Zero-COVID strategy in mainland China**

3

4 Fujian Song^{1*}, Max O. Bachmann¹

5 1. Norwich Medical School, University of East Anglia, Norwich, Norfolk, NR4 7TJ

6 * Correspondence to: Fujian Song, email: fujian.song@uea.ac.uk

7

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

8 **Abstract**

9 Background: China lifted strict non-pharmacological interventions (NPIs) to prevent outbreaks of
10 SARS-CoV-2 Omicron variants in December 2022. Relatively low levels of immunity and of vaccine
11 booster coverage in the Chinese population raise concerns that future outbreaks will rapidly result in
12 high rates of death and severe illness and will overwhelm health services.

13 Methods: This was a compartmental, discrete-time population dynamic model. It compared projected
14 deaths and hospitalisation under various scenarios, including booster vaccine coverage and strictness
15 of NPIs.

16 Results: We projected between 268,300 to 398,700 COVID-19 deaths, and peak numbers of
17 hospitalised severe/critical cases between 3.2 to 6.4 per 10,000 population, before the outbreak wave
18 recedes by February 2023. The COVID-19 deaths are reduced by 8% and 30%, respectively, under the
19 weak and strict NPI scenarios, compared with the scenario without NPI measures. Early achievement
20 of high coverage of three vaccine doses will further reduce COVID-19 deaths.

21 Conclusion: We projected fewer COVID-19 deaths and hospitalisations than some other models have.
22 Rapid expansion of booster vaccine coverage will only be effective if combined with strict NPIs
23 and/or the high coverage of booster vaccination could be achieved early.

24

25 **Introduction**

26 Since the outbreak of the COVID-19 epidemic in China, strict non-pharmaceutical interventions
27 (NPIs) have been implemented. The Dynamic zero-COVID strategy (DZCS), including mainly
28 community lockdown and mass scale nucleic acid testing, has been successfully controlled sporadic
29 outbreaks in China until November 2022. The reported total number of deaths from COVID-19 in
30 China was only 5235 by 06/12/2022 (total population >1.4 billion), compared to 212,766 by
31 25/11/2022 in the UK (total population 68.75 million). However, by November 2022, it had become
32 clear that the DZCS and its NPI measures are no longer able to control the transmission of SARS-
33 CoV-2 Omicron variants, and that the strategy is unsustainable due to its social and economic burdens.
34 Available evidence indicated that individuals infected with Omicron variants were mostly
35 asymptomatic, with few severe/critical cases, particularly among those fully vaccinated.^{1 2} For these
36 reasons, Chinese government started to adjust the COVID control strategy since 07/12/2022, to relax
37 the stringent lockdown NPI measures, and to encourage older adults to have booster shots of COVID
38 vaccines.³

39 Results of modelling studies have indicated that, without the strict NPI measures, the outbreak of
40 SARS-CoV-2 Omicron variants could result in one million or more deaths in China.⁴⁻⁶ In this
41 modelling study, we projected numbers of COVID-19 deaths and burdens to healthcare systems
42 caused by the Omicron outbreak immediately after easing NPI measures in China.

43 **Methods**

44 We revised and updated our model of effects of vaccination against COVID-19 in England,⁷ to
45 represent future outcomes of Omicron outbreaks in China. It is a compartmental, discrete-time (day)
46 population dynamic model (Supplementary Fig s1), implemented with computational language R.⁸
47 The population are classified into groups by age and COVID-19 vaccination status. The main infection
48 compartments are susceptible, exposed, infectious, and recovered. The population of China is assumed
49 to be susceptible to SARS-CoV-2 Omicron variant infection at the beginning of the simulation
50 (01/11/2022), including individuals previously vaccinated against SARS-CoV-2. The exposed
51 individuals are not infectious during the early incubation period, but start to be infectious before the
52 onset of symptoms. Individuals infected may have no symptoms (asymptomatic), or palpable
53 symptoms (symptomatic). Symptomatic patients are further classified into two categories: non-severe
54 and severe/critical cases. Asymptomatic and non-severe cases may be isolated at home or not, and
55 severe/critical symptomatic cases will need to be hospitalised, including those being admitted to
56 intensive care units (ICUs). Individuals recovered from Omicron variant infection will develop
57 immune responses against infection. In this short-term modelling study, the waning of protective
58 immunity from natural infection and vaccination is not considered. It is assumed that previous

59 vaccination against SARS-CoV-2 won't protect vaccinated individuals from the infection by Omicron
60 variant. However, vaccination will reduce infection severity and infection fatality.²

61 We estimated and calibrated the key infection transmission parameters based on a basic reproduction
62 number $R_0=8.3$,⁶ and parameters used in a recent modelling study of Omicron outbreaks in China
63 (Supplementary Table s1-s5).^{4,6} The primary outcomes are COVID-19 deaths and severe/critical cases
64 who need hospitalisation following the COVID-19 Omicron infection. The age-specific IFR and ISR
65 of unvaccinated individuals was estimated according to data on the SARS-CoV-2 Omicron outbreak in
66 Shanghai,¹ and effectiveness of vaccination with one, two and three doses of CoronaVac inactivated
67 vaccine from Hong Kong.² We used proportions of old people vaccinated with one, two and three
68 doses of vaccines in China according to a paper by Zang et al⁹ and official information release.¹⁰

69 Although the Chinese government started to ease the Zero-COVID measures from 07/12/2022,³ it is
70 unlikely that social activities could return to normal immediately, and the public are still very cautious
71 going to public places and face masker wearing remains universal. In addition, the proportion of adults
72 vaccinated with booster shot (three doses) will continue to increase in China. Because the rigorousness
73 of NPI measures in coming weeks remains unclear, we compared several hypothetical scenarios with a
74 range of different measures of NPI strictness after 07/12/2022 (Supplementary Table s5) and the
75 booster vaccination coverage achieved by 31/01/2023 (Supplementary Table s2).

76 **Results**


77 The projected COVID-19 deaths from 01/10/2022 to the end of the Omicron outbreak by February
78 2023 are from around 268,306 to 398,740 (Table 1 and Fig. 1a). The number of COVID-19 deaths
79 ranges from 190 to 283 per million population. The daily peak number of hospitalised severe/critical
80 cases ranged from 3.2 to 6.4 per 10,000 population (Table 1 and Fig. 1b). As expected, stricter NPI
81 measures are associated with more delayed and flattened outbreak peaks, and the outbreaks are
82 projected to end by February 2023 (Fig. 1). The COVID-19 deaths are reduced by 8-9% and 30%,
83 respectively, under the weak and strict NPI scenarios, compared with the scenario without NPI
84 measures. Compared with the moderate coverage of booster vaccination by 31/01/2023, the higher
85 coverage reduces COVID-19 deaths by 4.6%, 4.3% and 3.6%, respectively, under the strict, weak and
86 no NPI scenario. We also conducted an analysis by assuming an earlier reaching of high coverages of
87 booster vaccination by 10/12/2022, rather than by 31/01/2023 as assumed in the above analyses. If so,
88 the total COVID-19 deaths and the peak number of hospitalised cases could be further reduced by 6-
89 8%.

90

91 **Table 1. Projected total COVID-19 deaths, daily peak no. of severe cases hospitalised in China.**
 92 NPI measures after 07/12/2022 from strict (NPI-2), weak (NPI-1), to none (NPI-0), and their
 93 corresponding initial reproduction numbers were 2.51, 3.06, and 4.00 respectively. Booster
 94 vaccination coverage by 31/01/2023 is assumed to be moderate or high (see Supplementary Table s2)

Scenario	NPI strictness	Booster vaccine coverage by 31/01/2023	Cumulative COVID-19 deaths	COVID-19 deaths per million population	Daily peak hospitalised COVID-19 patients	Peak hospitalised patients per 10,000 population
NPI-21	Strict	Moderate	281,279	199.5	470,757	3.3
NPI-11	Weak	Moderate	364,940	258.9	681,407	4.8
NPI-01	None	Moderate	398,740	282.8	904,707	6.4
NPI-22	Strict	High	268,306	190.3	454,037	3.2
NPI-12	Weak	High	349,327	247.8	657,444	4.7
NPI-02	None	High	384,308	272.6	875,852	6.2

95
96



97
98
99 **Fig. 1: Projected cumulative COVID-19 deaths (Fig 1a) and daily number of hospitalised**
 100 **severe/critical cases (Fig 1b) under different strictness of non-pharmaceutical intervention**
 101 **measures after easing zero-COVID policy in China.** NPI measures after 07/12/2022 from strict
 102 (NPI-2), weak (NPI-1), to none (NPI-0); assumed moderate coverage of booster vaccinations by
 103 31/01/2023.

104

105

106 **Discussions**

107 Our modelling study projected COVID-19 deaths after easing zero-COVID strategy in China, which
108 range from 268,300 to 398,700, smaller than some other studies.^{5 6 11} We projected that the cumulative
109 number of COVID-19 deaths by February 2023 are 190-283 per million population, compared to 568-
110 770 per million by Leung et al,⁵ after lifting the zero-COVID measures. However, the total COVID-19
111 deaths in China was estimated to be from 225,453 to 293,127 by 01/04/2023 by IHME,¹² which is
112 smaller than ours. Differences in data and assumptions used may cause differences in the estimated
113 COVID-19 deaths. In addition, the diagnostic criteria of the COVID-19 deaths may be different across
114 countries and over time. COVID-19 deaths in our study is in line with the diagnostic criteria of
115 COVID-19 deaths in Shanghai between February and June 2022, given the data source of infection
116 fatality rates we used.¹

117 The projected daily peaks of hospitalised severe/critical cases range from around 454,000 to 905,000,
118 during the Omicron outbreak, which are below the number of hospital beds for respiratory illness (3.1
119 million) in China.⁴ A proportion of hospitalised COVID-19 patients will need ICU treatment, and the
120 currently available ICU beds (n=64,000) may not be sufficient. It should be noted that, additional to
121 the Omicron outbreak, the burden on hospital beds may further increase in the winter months due to
122 influenza and other respiratory infections.

123 Efforts to increase booster vaccination in older adults will reduce harmful outcomes of the Omicron
124 outbreak. Stricter NPI measures may acquire time for increasing the coverage of booster vaccination.
125 Because of great transmissibility of SARS-CoV-2 Omicron variants (R0 around 8), the effective
126 reproduction number after easing the zero-COVID policy is $R_t=2.53$ for the strictest NPI scenario used
127 in this study. Therefore, the full benefit of incremental improvement in booster vaccination are
128 difficult to achieve under the assumed NPI measures. If the higher coverage of booster vaccination
129 could be achieved earlier by 10/01/2023 rather than by 31/01/2023, the COVID-19 deaths and
130 hospitalisation burden could be further reduced by 6-8%.

131 China is a huge country with great diversities geographically and socioeconomically. Key estimates of
132 infection fatality and severity risk were based on data from Shanghai, in which healthcare systems
133 have better equipment and staff resources, compared with many other regions in China. In addition,
134 new SARS-CoV-2 variants may emerge, which should be closely monitored. Therefore, results of this
135 study may not be appropriate for specific regions or in future outbreaks. Outbreaks may occur early in
136 major cities, and relatively later in remote areas. Optimising the booster vaccination of the population
137 as early as possible, and maintaining appropriate NPI measures as strict as is feasible, will reduce
138 fatalities and burdens on healthcare systems caused by the inevitable Omicron outbreaks.

139

140 **Acknowledgement**

141 **Contributors:** FS designed, developed the model, retrieved data for estimating parameters, conducted
142 computational calculations, and prepared the draft manuscript. MOB provided methodological
143 support, helped interpret results and critically revised the draft manuscript. FS accepts full
144 responsibility for the work and/or the conduct of the study, had access to the data, and controlled the
145 decision to publish.

146 **Competing interests:** No competing interests declared.

147 **Funding:** There are no specific funding received for this study

148 **Data sharing statement:** All data relevant to the study are included in the article or uploaded as
149 online supplementary information. Computational R code is available from FS.

150

151 **References**

- 152 1. Chen X, Yan X, Sun K, et al. Estimation of disease burden and clinical severity of COVID-19
153 caused by Omicron BA.2 in Shanghai, February-June 2022. *Emerging microbes & infections*
154 2022;11(1):2800-07. doi: 10.1080/22221751.2022.2128435 [published Online First: 2022/10/08]
- 155 2. McMenamin ME, Nealon J, Lin Y, et al. Vaccine effectiveness of one, two, and three doses of
156 BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study.
157 *Lancet Infect Dis* 2022;22(10):1435-43. doi: 10.1016/s1473-3099(22)00345-0 [published Online First:
158 2022/07/20]
- 159 3. The State Council joint prevention and control mechanism against COVID-19. Notification of
160 further optimize scientific and precise intervention measures for the anti-COVID control. 2022
161 [Available from:
162 <http://www.nhc.gov.cn/xcs/gzccwj/202212/8278e7a7aee34e5bb378f0e0fc94e0f0.shtml>.
- 163 4. Cai J, Deng X, Yang J, et al. Modeling transmission of SARS-CoV-2 Omicron in China. *Nature*
164 *medicine* 2022;28(7):1468-75. doi: 10.1038/s41591-022-01855-7 [published Online First: 2022/05/11]
- 165 5. Kathy Leung, Gabriel M. Leung, Wu JT. Modelling the adjustment of COVID-19 response and exit
166 from dynamic zero-COVID in China. medRxiv : the preprint server for health sciences. 14/12/2022
167 ed, 2022.
- 168 6. Dennis Normile. In China, 'zero COVID' has become a Catch-22. Population chafes at control
169 measures, but lifting them now would carry huge risks (News). . *Science* (New York, NY)
170 2022;378(6624):1034.

- 171 7. Song F, Bachmann MO. Vaccination against COVID-19 and society's return to normality in
172 England: a modelling study of impacts of different types of naturally acquired and vaccine-induced
173 immunity. *BMJ open* 2021;11(11):e053507. doi: 10.1136/bmjopen-2021-053507 [published Online
174 First: 2021/11/18]
- 175 8. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical
176 Computing, Vienna, Austria. URL <https://www.R-project.org/>. 2019
- 177 9. Zang S, Zhang X, Qu Z, et al. Promote COVID-19 vaccination for older adults in China. *China*
178 *CDC Weekly* 2022;4(832-834)
- 179 10. State Council. COVID-19 vaccination in the elderly programme 2022 [Available from:
180 <https://www.mca.gov.cn/article/xw/mtbd/202212/20221200045237.shtml> accessed 05-12-2022.
- 181 11. Anonymous. Our model shows that China's covid death toll could be massive. It should act as a
182 wake-up call for the government. *The China Section, Lives on the lines. Economists*, 2022.
- 183 12. IHME. COVID-19 Projections: The Institute for Health Metrics and Evaluation (IHME) 2022
184 [21/12/2022]. Available from: [https://covid19.healthdata.org/china?view=cumulative-](https://covid19.healthdata.org/china?view=cumulative-deaths&tab=trend)
185 [deaths&tab=trend](https://covid19.healthdata.org/china?view=cumulative-deaths&tab=trend).
- 186

Modelling of outbreaks of SARS-CoV-2 Omicron variants after easing Dynamic Zero-COVID strategy in mainland China

Supplementary Files

1. Model structure and status


We revised and updated our existing model for vaccination against COVID-19 in England,⁷ using recently available data on Omicron variant of SARS-CoV-2 transmission and related health outcomes, to estimate the impact of changes in COVID-19 control policy in China.

It is a compartmental, discrete-time (day) population dynamic model (Supplementary Fig s1), implemented with computational language R.⁸ In this short-term modelling study, we assumed that the population will be constant, with balanced deaths and births, except deaths from COVID-19.

Population in China are assumed to be susceptible to SARS-CoV-2 Omicron variant infection at the beginning of the simulation (01/10/2022), including individuals previously vaccinated against SARS-CoV-2. Susceptible individuals may be infected by contacting infectious individuals, and the infection status is changed from “susceptible” (SU) to “exposed” (EX). The exposed individuals are not infectious during the early incubation period, but start to be infectious before the onset of symptoms. Individuals infected with SARS-CoV-2 virus may have no symptoms (ASYM), and palpable symptoms (symptomatic or clinical infections). Asymptomatic individuals can spread SARS-CoV-2 virus before recovery, although the transmission risk may be lower than symptomatic patients. Symptomatic patients are further classified into two categories: non-severe and severe/critical symptomatic cases. Asymptomatic individual may be isolated at home (ASYMq) or not (ASYM0). Non-severe symptomatic cases may be isolated (SYMq) or not (SYM0), and severe/critical symptomatic cases will need to be hospitalised (HOS) (including those being admitted to intensive care units (ICU)). Symptomatic patients are infectious and can transmit the virus to susceptible people before being isolated, hospitalised or recovered. We assume that hospitalised patients (HOS) are well isolated and no longer able to spread the virus to the susceptible population, although infectious patients who are self-isolated at home may transmit virus to household contacts.

Individuals may recover from infection of SARS-CoV-2 (RE). Individuals recovered from Omicron variant infection will develop immune responses against infection. In this short term (<6 months) modelling study, the waning of the protective immunity is not considered. It is assumed that vaccination against SARS-CoV-2 won't protect vaccinated individuals from being infected with Omicron variant. However, infection severity and fatality risk will be reduced among vaccinated individuals.

Fig s1: Modelling COVID-19 (omicron) epidemics in China – main compartments and transitions across status



Definitions of compartmental variables in Fig s1.

- SUS: susceptible individuals
- VAC1: vaccinated, dose-1
- VAC2: vaccinated, dose-2
- VAC3: vaccinated, dose-3
- EXsu: exposed susceptible individuals, not infectious
- Exv1: exposed vaccinated (dose-1), not infectious
- Exv2: exposed vaccinated (dose-2), not infectious
- Exv3: exposed vaccinated (dose-3), not infectious
- I0su: infectious, before symptom onset
- I0v1: infectious, before symptom onset, vaccinated dose-1
- I0v2: infectious, before symptom onset, vaccinated dose-2
- I0v3: infectious, before symptom onset, vaccinated dose-3
- ASYM: infectious, asymptomatic, with no or very mild symptoms
- ASYM0: asymptomatic cases not quarantined
- ASYMq: asymptomatic cases quarantined at home
- SYM: infectious, symptomatic cases
- SYM0: non-severe symptomatic patients who are not quarantined
- SYMq: non-severe symptomatic patients quarantined
- HOS: severe symptomatic patients who are hospitalised
- RE: recovered from covid-19 infection

Transition parameters in Fig s1:

- λ : Force of infection (λ) measures the risk (probability) of infection transmission.
- α_1 : rate of progressing from being exposed to being infectious.
- α_2 : rate of progressing from being asymptomatic infectious to symptomatic.
- μ : proportion of infected individuals who will be symptomatic; age-specific, and vaccine dose-specific

- ψ : proportion of severe/critical cases among symptomatic individuals, age-specific, and vaccine dose-specific
- pAq : proportion of quarantined individuals among asymptomatic individuals
- pSq : proportion of quarantined individuals among non-severe symptomatic individuals
- $\gamma a0$: rate of recovering for asymptomatic individuals
- $\gamma s0$: rate of recovering for non-severe symptomatic cases
- γsq : rate of being isolated in symptomatic patients
- γhI : rate of being hospitalised for severe symptomatic cases
- γsh : rate of being hospitalised for severe symptomatic patients

2. Transition parameters and distribution of infectious period

In Fig s1, force of infection (λ) measures the risk of infection,¹³ which is a function of transmission rate (η) and the prevalence of existing infectious individuals (I) among the population (N): $\lambda = \eta I / N$. The transmission rate η in the discrete-time model can be defined as the average number of new infected individuals generated daily by an infected person. That is, $\eta = Rt / T$, in which Rt is effective reproduction number and T is the average infectious period for infected individuals. We calculated η as a function of the number of daily contacts per person (c), and the risk of transmission per contact between a susceptible and an infected individual (q): $\eta = c * q$.^{14 15} For estimating age-specific transmission, q can be estimated according to known basic reproduction number ($R0$) and age-specific contact matrix, as $R0$ is the largest eigenvalue of the next generation matrix.¹⁵

The transition rate between model's compartments in infectious models is often assumed to be constant, calculated by $1/x$, in which "x" is the average period that subjects remain before the transition to the model's next compartments.¹³ Therefore, the infectious period in standard SIR or SEIR models is usually assumed to be exponentially distributed, with some limitations of the use of exponentially distributed infectious period.^{16 17} In this study, we assumed that the transition probability between model's compartments are based on gamma distributed periods that individuals remain in a compartment.¹⁸ The transition probability (y) at t is: $y_t = (cg_t - cg_{t-1}) / (1 - cg_t)$, where cg_t is the gamma cumulative probability by the end of t . Given mean and shape (k) parameters, the gamma distribution based transition probability is used to estimate the number of individuals moving between two status.

3. Parameterisation and data sources

Table s1: Population, proportion of symptomatic, severe/critical cases, and infection fatality risk (unvaccinated)

Data sources: Cai et al (2022),⁴ and Chen et al (2022).¹

Age	Population ⁴	Symptomatic rate ⁴	ISR(%) ¹	IFR(%) ¹
0-2	46730333	0.0716	0.0040	0.0010
3-11	155500009	0.0716	0.0040	0.0010
12-17	94764080	0.0716	0.0040	0.0010
18-24	104015331	0.0887	0.0400	0.0100
25-29	91847332	0.0887	0.0400	0.0100
30-34	124145190	0.0887	0.0400	0.0100
35-39	99012932	0.0887	0.0400	0.0100
40-44	92955330	0.1209	0.2800	0.0700
45-49	114224887	0.1209	0.2800	0.0700
50-54	121164296	0.1209	0.2800	0.0700
55-59	101400786	0.1209	0.2800	0.0700
60-64	73382938	0.1589	1.1400	0.3100
65-69	74005560	0.1589	1.1400	0.3100
70-79	80852004	0.1589	1.1400	0.3100
80+	35777716	0.1589	5.5500	2.2200

Table s2: Proportions of individuals received one, two and three doses of SARS-CoV-2 vaccines

Data sources: Zang et al,⁹ State Council,¹⁰ and estimated*. The vaccination coverage is defined as the proportion of individuals vaccinated >14 days before.

agrp	Aug 2022 ⁹			28 November 2022 ^{5 10}		
	Dose-1	Dose-2	Dose-3	Dose-1	Dose-2	Dose-3
0-2	0.000	0.000	0.000	0.000	0.000	0.000
3-11	0.300	0.200	0.000	0.400	0.300	0.000
12-17	0.400	0.300	0.000	0.600	0.500	0.000
18-24	0.900	0.850	0.450	0.950	0.900	0.570
25-29	0.900	0.850	0.450	0.950	0.900	0.570
30-34	0.900	0.850	0.450	0.950	0.900	0.570
35-39	0.900	0.850	0.450	0.950	0.900	0.570
40-44	0.900	0.850	0.450	0.950	0.900	0.570
45-49	0.900	0.850	0.450	0.950	0.900	0.570
50-54	0.900	0.850	0.450	0.950	0.900	0.570
55-59	0.900	0.850	0.450	0.950	0.900	0.570

60-64	0.904	0.856	0.678	0.950	0.864	0.687
65-69	0.904	0.856	0.678	0.950	0.864	0.687
70-79	0.904	0.856	0.678	0.950	0.864	0.687
80+	0.700	0.600	0.300	0.766	0.658	0.400

agrp	31/01/2023 – moderate scenario*			31/01/2023-higher scenario*		
	Dose-1	Dose-2	Dose-3	Dose-1	Dose-2	Dose-3
0-2	0.000	0.000	0.000	0.000	0.000	0.000
3-11	0.500	0.400	0.000	0.600	0.500	0.000
12-17	0.600	0.500	0.000	0.700	0.600	0.000
18-24	0.950	0.900	0.650	0.950	0.920	0.800
25-29	0.950	0.900	0.650	0.950	0.920	0.800
30-34	0.950	0.900	0.650	0.950	0.920	0.800
35-39	0.950	0.900	0.650	0.950	0.920	0.800
40-44	0.950	0.900	0.650	0.950	0.920	0.800
45-49	0.950	0.900	0.650	0.950	0.920	0.800
50-54	0.950	0.900	0.650	0.950	0.920	0.800
55-59	0.950	0.900	0.650	0.950	0.920	0.800
60-64	0.950	0.900	0.750	0.950	0.920	0.850
65-69	0.950	0.900	0.750	0.950	0.920	0.850
70-79	0.950	0.900	0.750	0.950	0.920	0.850
80+	0.850	0.800	0.500	0.950	0.920	0.800

Table s3: Effectiveness of CoronaVac vaccination in severity and mortality reduction

Data source: McMenamin et al ²

Age	Severity reduction			Mortality reduction			Mid/moderate disease		
	Dose-1	Dose-2	Dose-3	Dose-1	Dose-2	Dose-3	Dose-1	Dose-2	Dose-3
<60	0.748	0.917	0.988	0.782	0.933	0.994	0.327	0.251	0.51
60_69	0.542	0.793	0.974	0.656	0.843	0.99	0	0	0.324
70_79	0.292	0.743	0.954	0.453	0.767	0.97	0	0	0.324
80+	0.39	0.582	0.973	0.448	0.63	0.979	0	0	0.324

Table s4: Estimates of transition parameters

Data sources: Song & Bachmann 2021,⁷ and Cai et al 2022.⁴

Transition parameter	Value	Source
----------------------	-------	--------

Basic reproduction number	8.3	Based on the R_0 (7.0 and 8.3) used in Leung et al. ⁵
Serial interval (sd)	3.0 (2.3)	Backer et al (2022) ¹⁹ For R package EpiEstim to estimate R_t .
Incubation period	3.42	Wu et al (2022) ²⁰
Incubation days: non-infectious	2.42 (sd 1.556)	
Incubation days: infectious	1.00 (sd 1.00)	
Average infectious days	5	Hakki et al (2022) ²¹
Asymptomatic: Infectious days without isolation	4.00 (2.00)	
Asymptomatic: Infectious days before being isolated	2.00 (1.414)	
Symptomatic: Infectious days without quarantine	4.00 (2.00)	
Symptomatic: Infectious days before being quarantined	1.00 (1.00)	
Symptomatic: Quarantine to recovery days	3.00 (1.732)	
Severe/critical cases: days before hospitalisation	2.20 (1.483)	Cai et al (2022) ⁴
Length of hospital stay	8.00 (2.828)	Cai et al (2022) ⁴
Days from being infected to death	11.40 (4.654)	Cai et al (2022) ⁴

4. Model verification/calibration

Based on the basic reproduction number ($R_0=8.3$)⁵ and the pre-pandemic contact matrix in China,⁴ we estimated the risk of transmission per contact ($q=0.586$). We run the basic simulation with 60 imported seeds on 01/10/2022, and calibrated parameters for NPI scaling factors in Table s5. The simulated incidence of new infected individuals was 26,600, which was close to the reported 25,321 on 06/12/2022, under the strict Dynamic Zero-COVID strategy in mainland China (http://www.nhc.gov.cn/xcs/yqtb/list_gzbd.shtml). Using R package EpiEstim and the simulated incidence of infected individuals, the effective reproduction number before 07/12/2022 was around $R_t=1.41$.

5. Projection scenarios

The Chinese government started to relax dynamic Zero-COVID policy from 07/12/2022.³ However, it is unlikely that the society and social activities could return to normal immediately, as some non-pharmaceutical intervention (NPI) measures will remain, and the public are still very cautious in going out. Face masker wearing is nearly universal, and access to some public places is still restricted. Because the strictness of NPI measures in next many weeks is unclear, we assumed three NPI scenarios, respectively, with strict, weak and no NPI measures (Table s5). The early stage R_t corresponding to each of the assumed scenarios are, respectively, 2.53, 3.09, and 4.00.

Considering that the proportion of adults vaccinated with three doses will continue to increase, we assumed two scenarios with moderate or higher levels of booster vaccines in the population by 31 January 2023 (Table s2). Therefore, simulation scenarios are a combination of NPI measures after relaxing dynamic zero-COVID policy (Table s5) and whether the coverage of booster vaccine is moderate or higher by 31 January 2023 (Table s2).

Table s5: Non-pharmaceutical interventions measures (NPI) related parameters

Data sources: Contacts at home was assumed to be 20% of the general contacts. Risk of transmission per contact was reduced by $q' = q \cdot (1-c)$, in which c is a coefficient, ranging from 0 to 1, as shown in the table.

Parameters	Age	Non-pharmaceutical intervention measures			
		NPI - zero COVID	NPI strict	NPI weak	No NPI
		Before 07/12//2022	from 07/12/2022	from 07/12/2022	from 07/12/2022
Proportion of quarantined asymptomatic cases	0-17	0.920	0.600	0.200	0.050
	18-59	0.920	0.600	0.200	0.050
	60-69	0.920	0.600	0.200	0.050
	>70	0.920	0.600	0.200	0.050
Proportion of quarantined symptomatic cases	0-17	0.980	0.800	0.600	0.200
	18-59	0.980	0.800	0.600	0.200
	60-69	0.980	0.800	0.600	0.200
	>70	0.980	0.800	0.600	0.200
Scaling factor for reduced q and contacts	0-17	0.910	0.700	0.500	0.00
	18-59	0.890	0.600	0.400	0.00
	60-69	0.930	0.700	0.500	0.00
	70+	0.950	0.800	0.600	0.00

6. References in supplementary material

1. Song F, Bachmann MO. Vaccination against COVID-19 and society's return to normality in England: a modelling study of impacts of different types of naturally acquired and vaccine-induced immunity. *BMJ open* 2021;11(11):e053507. doi: 10.1136/bmjopen-2021-053507 [published Online First: 2021/11/18]
2. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>. 2019
3. Rock K, Brand S, Moir J, et al. Dynamics of infectious diseases. *Rep Prog Phys* 2014;77(2):026602. doi: 10.1088/0034-4885/77/2/026602 [published Online First: 2014/01/22]
4. Tuckwell HC, Williams RJ. Some properties of a simple stochastic epidemic model of SIR type. *Math Biosci* 2007;208(1):76-97. doi: 10.1016/j.mbs.2006.09.018 [published Online First: 2006/12/19]
5. Wallinga J, Teunis P, Kretzschmar M. Using data on social contacts to estimate age-specific transmission parameters for respiratory-spread infectious agents. *Am J Epidemiol* 2006;164(10):936-44. doi: 10.1093/aje/kwj317 [published Online First: 2006/09/14]
6. Grant A. Dynamics of COVID-19 epidemics: SEIR models underestimate peak infection rates and overestimate epidemic duration. medRxiv preprint doi: <https://doi.org/10.1101/2020040220050674> 2020
7. Krylova O, Earn DJD. Effects of the infectious period distribution on predicted transitions in childhood disease dynamics. *J R Soc Interface* 2013;10(84):20130098-98. doi: 10.1098/rsif.2013.0098
8. Davies NG, Kucharski AJ, Eggo RM, et al. Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: a modelling study. *The Lancet Public health* 2020;5(7):e375-e85. doi: 10.1016/s2468-2667(20)30133-x [published Online First: 2020/06/06]
9. Cai J, Deng X, Yang J, et al. Modeling transmission of SARS-CoV-2 Omicron in China. *Nature medicine* 2022;28(7):1468-75. doi: 10.1038/s41591-022-01855-7 [published Online First: 2022/05/11]
10. Chen X, Yan X, Sun K, et al. Estimation of disease burden and clinical severity of COVID-19 caused by Omicron BA.2 in Shanghai, February-June 2022. *Emerging microbes & infections* 2022;11(1):2800-07. doi: 10.1080/22221751.2022.2128435 [published Online First: 2022/10/08]
11. Zang S, Zhang X, Qu Z, et al. Promote COVID-19 vaccination for older adults in China. *China CDC Weekly* 2022;4(832-834)

12. State Council. COVID-19 vaccination in the elderly programme 2022 [Available from: <https://www.mca.gov.cn/article/xw/mtbd/202212/20221200045237.shtml> accessed 05-12-2022.
13. Kathy Leung, Gabriel M. Leung, Wu JT. Modelling the adjustment of COVID-19 response and exit from dynamic zero-COVID in China. medRxiv : the preprint server for health sciences. 14/12/2022 ed, 2022.
14. McMenamin ME, Nealon J, Lin Y, et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study. *Lancet Infect Dis* 2022;22(10):1435-43. doi: 10.1016/s1473-3099(22)00345-0 [published Online First: 2022/07/20]
15. Backer JA, Eggink D, Andeweg SP, et al. Shorter serial intervals in SARS-CoV-2 cases with Omicron BA.1 variant compared with Delta variant, the Netherlands, 13 to 26 December 2021. *Euro Surveill* 2022;27(6) doi: 10.2807/1560-7917.Es.2022.27.6.2200042 [published Online First: 2022/02/12]
16. Wu Y, Kang L, Guo Z, et al. Incubation Period of COVID-19 Caused by Unique SARS-CoV-2 Strains: A Systematic Review and Meta-analysis. *JAMA network open* 2022;5(8):e2228008. doi: 10.1001/jamanetworkopen.2022.28008 [published Online First: 2022/08/23]
17. Hakki S, Zhou J, Jonnerby J, et al. Onset and window of SARS-CoV-2 infectiousness and temporal correlation with symptom onset: a prospective, longitudinal, community cohort study. *Lancet Respir Med* 2022;10(11):1061-73. doi: 10.1016/s2213-2600(22)00226-0 [published Online First: 2022/08/22]
18. The State Council joint prevention and control mechanism against COVID-19. Notification of further optimize scientific and precise intervention measures for the anti-COVID control. 2022 [Available from: <http://www.nhc.gov.cn/xcs/gzccwj/202212/8278e7a7aee34e5bb378f0e0fc94e0f0.shtml>.